Cyteir Therapeutics, Inc. announced that the first patient has been dosed in a Phase 2 expansion cohort study of CYT-0851 monotherapy that is part of the Phase 1/2 trial. CYT-0851 is being evaluated for the treatment of hematologic malignancies and solid tumors. CYT-0851 is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

For the Phase 2 monotherapy expansion cohort study with CYT-0851 (NCT Number NCT03997968), intend to enroll in six disease-specific cohorts in hematologic malignancies (relapsed and/or refractory diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma) and solid tumors (recurrent metastatic or locally advanced pancreatic cancer, progressive ovarian cancer, and metastatic soft tissue sarcoma). The Phase 2 study is being run with a Simon two-stage design and patients will be dosed with the recommended Phase 2 dose of CYT-0851 of 400 mg once daily that was determined in the Phase 1 dose escalation study. The objectives of the expansion cohort study are to evaluate preliminary anti-tumor activity in each disease specific expansion cohort, and to confirm the safety of the chosen Phase 2 dose.